Cargando…

An outbreak of extremely drug-resistant Pseudomonas aeruginosain a tertiary care pediatric hospital in Italy

BACKGROUND: Extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) isolates are susceptible to only one or two classes of antibiotics. In 2011–2012, we investigated an outbreak of XDR-PA affecting children with onco-hematological diseases. METHODS: Outbreak investigation included ascertainment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciofi degli Atti, Marta, Bernaschi, Paola, Carletti, Michaela, Luzzi, Ida, García-Fernández, Aurora, Bertaina, Alice, Sisto, Annamaria, Locatelli, Franco, Raponi, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167521/
https://www.ncbi.nlm.nih.gov/pubmed/25209325
http://dx.doi.org/10.1186/1471-2334-14-494
_version_ 1782335434705076224
author Ciofi degli Atti, Marta
Bernaschi, Paola
Carletti, Michaela
Luzzi, Ida
García-Fernández, Aurora
Bertaina, Alice
Sisto, Annamaria
Locatelli, Franco
Raponi, Massimiliano
author_facet Ciofi degli Atti, Marta
Bernaschi, Paola
Carletti, Michaela
Luzzi, Ida
García-Fernández, Aurora
Bertaina, Alice
Sisto, Annamaria
Locatelli, Franco
Raponi, Massimiliano
author_sort Ciofi degli Atti, Marta
collection PubMed
description BACKGROUND: Extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) isolates are susceptible to only one or two classes of antibiotics. In 2011–2012, we investigated an outbreak of XDR-PA affecting children with onco-hematological diseases. METHODS: Outbreak investigation included ascertainment of cases, tracing of intestinal carriers and environmental surveillance. Contact precautions were adopted for patients with infection or colonization. Isolates were tested for antimicrobial susceptibility; phenotypic confirmation of carbapenemase production was performed, and carbapenemase genes were tested by multiplex polymerase-chain-reaction (PCR). Genotypes were determined by pulsed-field gel electrophoresis (PFGE). RESULTS: XDR-PA was isolated from 27 patients; 12 had bacteremia, 6 other infections and 9 were colonized. Severe neutropenia was significantly associated with bacteremia. Bloodstream-infection mortality rate was 67%. All isolates were resistant to carbapenems, cephalosporins and penicillins + β-lactamase inhibitors. Isolates were susceptible only to colistin in 22 patients, to colistin and amikacin in 4, and to ciprofloxacin and colistin in 1. PFGE results identified 6 subtypes of a single genotype, associated with clusters of cases, and 4 sporadic genotypes. Two sporadic isolates were metallo-β-lactamase producers, negative to PCR. All other isolates were metallo-β-lactamase producers due to the presence of a VIM carbapenemase. Incidence of XDR-PA infections decreased from 0.72 cases/1,000 inpatient-days in March 2011-March 2012, to 0.34/1,000 in April-December 2012, after implementation of active finding of intestinal carriers on all onco-hematological inpatients. CONCLUSIONS: Control measures targeting intestinal carriers are crucial in limiting in-hospital transmission of XDR-PA polyclonal strains, protecting more vulnerable patients, such as severely neutropenic children, from developing clinical infections. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-494) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4167521
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41675212014-09-19 An outbreak of extremely drug-resistant Pseudomonas aeruginosain a tertiary care pediatric hospital in Italy Ciofi degli Atti, Marta Bernaschi, Paola Carletti, Michaela Luzzi, Ida García-Fernández, Aurora Bertaina, Alice Sisto, Annamaria Locatelli, Franco Raponi, Massimiliano BMC Infect Dis Research Article BACKGROUND: Extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) isolates are susceptible to only one or two classes of antibiotics. In 2011–2012, we investigated an outbreak of XDR-PA affecting children with onco-hematological diseases. METHODS: Outbreak investigation included ascertainment of cases, tracing of intestinal carriers and environmental surveillance. Contact precautions were adopted for patients with infection or colonization. Isolates were tested for antimicrobial susceptibility; phenotypic confirmation of carbapenemase production was performed, and carbapenemase genes were tested by multiplex polymerase-chain-reaction (PCR). Genotypes were determined by pulsed-field gel electrophoresis (PFGE). RESULTS: XDR-PA was isolated from 27 patients; 12 had bacteremia, 6 other infections and 9 were colonized. Severe neutropenia was significantly associated with bacteremia. Bloodstream-infection mortality rate was 67%. All isolates were resistant to carbapenems, cephalosporins and penicillins + β-lactamase inhibitors. Isolates were susceptible only to colistin in 22 patients, to colistin and amikacin in 4, and to ciprofloxacin and colistin in 1. PFGE results identified 6 subtypes of a single genotype, associated with clusters of cases, and 4 sporadic genotypes. Two sporadic isolates were metallo-β-lactamase producers, negative to PCR. All other isolates were metallo-β-lactamase producers due to the presence of a VIM carbapenemase. Incidence of XDR-PA infections decreased from 0.72 cases/1,000 inpatient-days in March 2011-March 2012, to 0.34/1,000 in April-December 2012, after implementation of active finding of intestinal carriers on all onco-hematological inpatients. CONCLUSIONS: Control measures targeting intestinal carriers are crucial in limiting in-hospital transmission of XDR-PA polyclonal strains, protecting more vulnerable patients, such as severely neutropenic children, from developing clinical infections. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-494) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-10 /pmc/articles/PMC4167521/ /pubmed/25209325 http://dx.doi.org/10.1186/1471-2334-14-494 Text en © Ciofi degli Atti et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ciofi degli Atti, Marta
Bernaschi, Paola
Carletti, Michaela
Luzzi, Ida
García-Fernández, Aurora
Bertaina, Alice
Sisto, Annamaria
Locatelli, Franco
Raponi, Massimiliano
An outbreak of extremely drug-resistant Pseudomonas aeruginosain a tertiary care pediatric hospital in Italy
title An outbreak of extremely drug-resistant Pseudomonas aeruginosain a tertiary care pediatric hospital in Italy
title_full An outbreak of extremely drug-resistant Pseudomonas aeruginosain a tertiary care pediatric hospital in Italy
title_fullStr An outbreak of extremely drug-resistant Pseudomonas aeruginosain a tertiary care pediatric hospital in Italy
title_full_unstemmed An outbreak of extremely drug-resistant Pseudomonas aeruginosain a tertiary care pediatric hospital in Italy
title_short An outbreak of extremely drug-resistant Pseudomonas aeruginosain a tertiary care pediatric hospital in Italy
title_sort outbreak of extremely drug-resistant pseudomonas aeruginosain a tertiary care pediatric hospital in italy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167521/
https://www.ncbi.nlm.nih.gov/pubmed/25209325
http://dx.doi.org/10.1186/1471-2334-14-494
work_keys_str_mv AT ciofidegliattimarta anoutbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT bernaschipaola anoutbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT carlettimichaela anoutbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT luzziida anoutbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT garciafernandezaurora anoutbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT bertainaalice anoutbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT sistoannamaria anoutbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT locatellifranco anoutbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT raponimassimiliano anoutbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT ciofidegliattimarta outbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT bernaschipaola outbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT carlettimichaela outbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT luzziida outbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT garciafernandezaurora outbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT bertainaalice outbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT sistoannamaria outbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT locatellifranco outbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly
AT raponimassimiliano outbreakofextremelydrugresistantpseudomonasaeruginosainatertiarycarepediatrichospitalinitaly